FURIN and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: Perhaps, in the future these drugs might be also tried more specifically on mouse models or patients affected by dystroglycanopathies, although a dangerous undesired effect of these protease inhibitors could be to inhibit the furin-driven proteolysis of the N-terminal domain of α-DG that seems to represent a necessary step along its maturation pathway [21].